Sanofi snaps up new vaccine candidate and devises mRNA game plan around it — but not for what you think
Paul Hudson has spotlighted vaccines, immunology and dermatology as some of the top R&D focuses at Sanofi. His latest deal brings all of them together.
The French pharma giant isn’t sharing any financial details about the buyout of Origimm, a low-profile, private Austrian biotech whose technology promises to identify antigens causing skin disease and build vaccines against them. Their lead candidate targets acne vulgaris.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.